Walleye Capital’s Biolase, Inc. BIOL Stock Holding History

Walleye Capital’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-16,934	Closed	-$31.5K	–	5664
2023 Q3	$31.5K	Buy	16,934 +2,729	+19%	+$14.4K	﹤0.01%	4302
2023 Q2	$100K	Buy	+14,205	New	+$238K	﹤0.01%	3428

Other funds holding BIOL

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KWA

Kellett Wealth Advisors Cincinnati, Ohio $215M AUM 22.03% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Zhang Financial Portage, Michigan $2.89B AUM 18.44% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Walleye Capital's BIOL Position: Q4 2023 in Review

Walleye Capital sold out of Biolase, Inc. (BIOL) in Q4 2023, closing a stake of 16,934 shares — an estimated $31.5K sold.

Walleye Capital first reported a position in BIOL in Q2 2023 and held it in 2 quarters. The position peaked at $100K in Q2 2023. 16 funds tracked by Wall St. Rank hold BIOL as of Q4 2023.

Walleye Capital reported no remaining Biolase, Inc. position as of Q4 2023 after selling out during the quarter.
Walleye Capital sold 16,934 Biolase, Inc. shares in Q4 2023, an estimated $31.5K.
Walleye Capital first reported a position in Biolase, Inc. in Q2 2023 and held it in 2 quarters.
Walleye Capital's Biolase, Inc. position peaked at $100K in Q2 2023.
16 funds tracked by Wall St. Rank held Biolase, Inc. as of Q4 2023.

Based on Walleye Capital's 13F filing for Q4 2023, filed 14 Feb 2024.